The purpose of this study is to monitor safety outcomes for patients being treated with intravitreal aflibercept injections for choroidal neovascularization secondary to Presumed Ocular Histoplasmosis Syndrome.

Inclusion Criteria:

• Active choroidal neovascularization (CNV) secondary to presumed ocular histoplasmosis demonstrated by active leakage on fluorescein angiography with spectal domain OCT evidence of subretinal or intraretinal fluid or PED.
• Active CNV may also be defined as demonstrating active subretinal hemorrhage.
• ETDRS Best corrected visual acuity 20/20-20/320.
• willing and able to comply with all study clinic visits and study related procedures.
• Willing to use and practice more than one form of contraceptives during the 13 month study for male and female.
• Provide signed informed consent
• Able to understand and complete study related questionnaires

Exclusion Criteria:

• Under 18 years of age
• CNV due to other causes than Presumed Ocular Histoplasmosis
• Previous treatment in the study eye within 6 months prior to Day 1
• More than 5 Intravitreal injections of anti-VEGF therapy within previous 12 months
• Any clinical evidence of any other ocular condition other than Ocular histoplasmosis
• History of allergy to fluorescein
• Pregnant( or planning on becoming pregnant within the next 13 months) or breast feeding women
• Sexually Active Men or Women who are NOT willing to practice more than one form of contraceptives during the next 13 months.
• Anticipated or previous (within previous 3 months) systemic anti-VEGF therapy